Phase 3 Readout

RGNX: Phase 3 Topline: A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and

Name: Phase 3 Topline: A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and
Start: 2028-06-01
End: 2028-06-01

June 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 1, 2028
Company: REGENXBIO Inc. (RGNX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and

June 1, 2028

RGNX overview →

Company: REGENXBIO Inc. (RGNX)
Indication: Duchenne Muscular Dystrophy